Westwood Holdings Group’s Nektar Therapeutics NKTR Stock Holding History

Westwood Holdings Group’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-100	Closed	-$29K	–	482
2017 Q2	$29K	Buy	+100	New	+$28.9K	﹤0.01%	469

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Westwood Holdings Group's NKTR Position: Q3 2017 in Review

Westwood Holdings Group sold out of Nektar Therapeutics (NKTR) in Q3 2017, closing a stake of 100 shares — an estimated $29K sold.

Westwood Holdings Group first reported a position in NKTR in Q2 2017 and held it in 1 quarter. The position peaked at $29K in Q2 2017. 203 funds tracked by Wall St. Rank hold NKTR as of Q3 2017.

Westwood Holdings Group reported no remaining Nektar Therapeutics position as of Q3 2017 after selling out during the quarter.
Westwood Holdings Group sold 100 Nektar Therapeutics shares in Q3 2017, an estimated $29K.
Westwood Holdings Group first reported a position in Nektar Therapeutics in Q2 2017 and held it in 1 quarter.
Westwood Holdings Group's Nektar Therapeutics position peaked at $29K in Q2 2017.
203 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2017.

Based on Westwood Holdings Group's 13F filing for Q3 2017, filed 14 Nov 2017.